What is Climb Bio, Inc.'s D&A?

Climb Bio, Inc. (CLYM) reported D&A of $38K in Q1 2026.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Climb Bio, Inc. CLYM D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

AmgenAMGN

$1.12B-19.5%

Vera TherapeuticsVERA

$140K+64.7%

Kyverna Therapeutics, Inc.KYTX

$351K-29.9%

Cullinan Therapeutics, Inc.CGEM

$79K+3.9%

Jade Biosciences, Inc. Common StockJBIO

$9K+125%

Other financials

Income statement

See full

Operating income-$15.2M+33.9%

Net income-$13.7M+34.0%

EPS (diluted)-$0.20+35.5%

Balance sheet

See full

Cash & equivalents$8.4M-71.2%

Total debt$479.0K+1.1%

Total equity$148.1M-23.4%

Total assets$152.4M-24.1%

Cash flow

See full

Operating cash flow-$14.4M+6.8%

CapEx$109.0K—

Free cash flow-$15.6M-183%

Valuation

See full

Market cap$724.95M+787%

Enterprise value$717.07M+1,247%

Returns & leverage

See full

Return on equity-30.9%-10.3pp

Debt / equity0×0.0×

Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Climb Bio, Inc.'s D&A?: Climb Bio, Inc. (CLYM) reported D&A of $38K in Q1 2026.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.